Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort

This naturalistic study analysed the association between cumulative lifetime antipsychotic dose and cognition in schizophrenia after an average of 16.5 years of illness. Sixty participants with schizophrenia and 191 controls from the Northern Finland Birth Cohort 1966 were assessed at age 43 years with a neurocognitive test battery. Cumulative lifetime antipsychotic dose-years were collected from medical records and interviews. The association between antipsychotic dose-years and a cognitive composite score based on principal component analysis was analysed using linear regression. Higher lifetime antipsychotic dose-years were significantly associated with poorer cognitive composite score, when adjusted for gender, onset age and lifetime hospital treatment days. The effects of typical and atypical antipsychotics did not differ. This is the first report of an association between cumulative lifetime antipsychotic dose and global cognition in midlife schizophrenia. Based on these data, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance at age 43 years. Potential biases related to the naturalistic design may partly explain the results; nonetheless, it is possible that large antipsychotic doses harm cognition in schizophrenia in the long-term.Peer reviewe

The Port of Vancouver - Just a Pawn in the Game of Commerce?

Greater Vancouver is home to one of the largest ports in North America and some of the most modern container terminals in the world, the Port of Vancouver. Every year, the Port of Vancouver trades approximately $43 billion with more than 90 economies, creates jobs for approximately 70,000 Canadians, contributes almost$4 billion to Canada's GDP, and generates $763 million in tax revenue. By working together to maximize the opportunities being presented, the Port hopes to triple its benefits within 15 years (Vancouver Port Authority 2005). Increasing container trade with Asia, and specifically China, makes containers the Port of Vancouver’s fastest growing sector, - a growth which is not expected to subside significantly over the next two decades. Container handlings facilities on the Lower Mainland are, accordingly, being expanded and developed to capitalize on this major market opportunity and the considerable economic benefits it represent (Greater Vancouver Short-Sea Container Shipping Study). But at the same time the Port of Vancouver is at a crossroads. Despite their vast potential, Vancouver’s advantages are being jeopardized by freight congestion in the Lower Mainland, and alarming concerns about capacity to handle the projected trade growth over the next 20 years. Although a major road transportation improvement is planned on the Lower Mainland, trucking and railways companies are expected to face increasing challenges in the future to move containers in a timely manner and at reasonable rates. The need for an integrated multimodal transportation system that efficiently and safely moves goods and people while respecting the environment are for that reason highly critical if the Port of Vancouver wants to be a part of the global transportation game

Twenty Years of Schizophrenia Research in the Northern Finland Birth Cohort 1966: A Systematic Review

Birth cohort designs are useful in studying adult disease trajectories and outcomes, such as schizophrenia. We review the schizophrenia research performed in the Northern Finland Birth Cohort 1966 (NFBC 1966), which includes 10,934 individuals living in Finland at 16 years of age who have been monitored since each mother’s mid-pregnancy. By the age of 44, 150 (1.4%) had developed schizophrenia. There are 77 original papers on schizophrenia published from the NFBC 1966. The early studies have found various risk factors for schizophrenia, especially related to pregnancy and perinatal phase. Psychiatric and somatic outcomes were heterogeneous, but relatively poor. Mortality in schizophrenia is high, especially due to suicides. Several early predictors of outcomes have also been found. Individuals with schizophrenia have alterations in brain morphometry and neurocognition, and our latest studies have found that the use of high lifetime doses of antipsychotics associated with these changes. The schizophrenia research in the NFBC 1966 has been especially active for 20 years, the prospective study design and long follow-up enabling several clinically and epidemiologically important findings. When compared to other birth cohorts, the research in the NFBC 1966 has offered also unique findings on course and outcome of schizophrenia

Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort

Abstract This naturalistic study analysed the association between cumulative lifetime antipsychotic dose and cognition in schizophrenia after an average of 16.5 years of illness. Sixty participants with schizophrenia and 191 controls from the Northern Finland Birth Cohort 1966 were assessed at age 43 years with a neurocognitive test battery. Cumulative lifetime antipsychotic dose-years were collected from medical records and interviews. The association between antipsychotic dose-years and a cognitive composite score based on principal component analysis was analysed using linear regression. Higher lifetime antipsychotic dose-years were significantly associated with poorer cognitive composite score, when adjusted for gender, onset age and lifetime hospital treatment days. The effects of typical and atypical antipsychotics did not differ. This is the first report of an association between cumulative lifetime antipsychotic dose and global cognition in midlife schizophrenia. Based on these data, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance at age 43 years. Potential biases related to the naturalistic design may partly explain the results; nonetheless, it is possible that large antipsychotic doses harm cognition in schizophrenia in the long-term